US Stock Market Update | Redhill Biopharma surges 18% as opaganib shows potential for obesity-related diseases
Redhill Biopharma announced positive results from multiple in vivo studies. These studies support the potential clinical applications of opaganib in the prevention and treatment of type 2 diabetes and other obesity-related diseases. As of the time of writing, Redhill surged 17.89% in early trading to $0.342. The research results demonstrate the benefits of opaganib therapy in inhibiting weight gain, reduced glucose tolerance, and fat deposition induced by HFD (high-fat diet). Furthermore, in HFD models already obese, opaganib therapy can slow weight gain and restore glucose tolerance
According to the latest update from VETIMES Finance App, Redhill Biopharma (RDHL.US) has announced positive results from multiple in vivo studies. These studies support the potential clinical applications of opaganib in the prevention and treatment of type 2 diabetes and other obesity-related diseases. At the time of writing, Redhill's stock surged by 17.89% in early trading, reaching $0.342.
The research results demonstrate the benefits of opaganib therapy in inhibiting weight gain induced by HFD (high-fat diet), reducing glucose tolerance, and fat deposition.
Furthermore, in HFD models already obese, opaganib therapy can slow down weight gain and restore glucose tolerance